• 服務(wù)熱線

    15021010459
    技術(shù)文章
    當(dāng)前位置:主頁(yè) > 技術(shù)文章 > Ariad抗癌藥Iclusig重返市場(chǎng)

    Ariad抗癌藥Iclusig重返市場(chǎng)

    更新時(shí)間:2014-01-20 點(diǎn)擊次數(shù):1508

        去年Ariad Pharmaceuticals公司業(yè)績(jī)由于主打抗癌藥物Iclusig被緊急下架而遭受重創(chuàng)。公司一度陷入困境并將其在美國(guó)的員工裁員160人,約占美 國(guó)分部總員工數(shù)的40%,以節(jié)省開支。不過(guò)現(xiàn)在Ariad Pharmaceuticals公司迎來(lái)一絲曙光。公司已經(jīng)著手將Iclusig重新推向市場(chǎng)。此次Ariad將把Iclusig的適用癥范圍縮小,并在 藥物包裝上標(biāo)明可能出現(xiàn)的副作用如心臟病、血液凝塊等。不過(guò)由于Iclusig適用范圍變小,公司的收入可能也會(huì)大受影響。為解決這一問(wèn)題公司計(jì)劃申請(qǐng)重 啟此前被FDA下令暫停的關(guān)于Iclusig治療慢性白血病的研究計(jì)劃以達(dá)到亡羊補(bǔ)牢的作用。

        不過(guò)Ariad Pharmaceuticals公司的這一系列舉措能否獲得預(yù)期效果還需要等待公司2014年*季度財(cái)報(bào)公布后才能知曉。

    詳細(xì)英文報(bào)道:

        Last year, Ariad Pharmaceuticals ($ARIA) watched more than $2.5 billion melt off its market cap when the cancer-fighting Iclusig began a downward spiral that would eventually remove it from the market. But now begins the rebuilding project, as the Cambridge, MA, drugmaker has relaunched its sole product with a lot of ground to make up.

        The drug is now indicated for a smaller group of leukemia patients than before, and it carries a serious boxed warning about the risk of clotting and heart failure that got it pulled from shelves in the fall. But it is for sale, and that puts Ariad in a better place than many predicted at its nadir.

        "We are back on track," CEO Harvey Berger told Bloomberg last month. "We'll enter 2014 largely where we were as we started off the fall in September."

        Of course, that's not entirely the case. Losing more than half of its value forced Ariad to considerably thin its ranks, laying off 40% of its U.S. workforce--or 160 employees--in an effort to save $26 million. Now the company plans to gradually ramp up stateside sales with the help of specialty pharmacy Biologics, Inc., first looking to transition the case-by-case patients who were still using the drug during its marketing hiatus.

        And the company has a long way to go on the R&D side. When the storm over Iclusig began, Ariad was in the process of testing the drug in a broader population, but an FDA-imposed clinical hold led the company to discontinue a Phase III study on patients with newly diagnosed chronic myeloid leukemia and put the brakes on a fleet of Phase II studies designed to expand the drug's market. Berger has said that Ariad is yet to decide just how to move forward with its paused programs.

        Still, the biotech is undeniably sitting prettier than it was just two months ago, and its next big test will come when Q1 sales figures roll in.——(華雅干細(xì)胞整理報(bào)道)

    2025 版權(quán)所有 © 重慶市華雅干細(xì)胞技術(shù)有限公司  備案號(hào):渝ICP備14000349號(hào)-4 sitemap.xml 管理登陸 技術(shù)支持:化工儀器網(wǎng)

    地址:重慶市江北區(qū)金渝大道153號(hào)8棟20-14 傳真:023-63419626 郵件:sales@ys-bio.com

    重慶市華雅干細(xì)胞技術(shù)有限公司主要經(jīng)營(yíng)干細(xì)胞研究 干細(xì)胞治療產(chǎn)品 生物試劑 實(shí)驗(yàn)耗材 藥物研發(fā)等產(chǎn)品。

    關(guān)注我們

    服務(wù)熱線

    400-021-2200

    掃一掃,關(guān)注我們

    主站蜘蛛池模板: 国产乱人伦偷精品视频免下载| 亚洲一区精品中文字幕| 久久99精品国产麻豆宅宅| 九色精品视频在线观看| 国产夫妇精品自在线| 夜夜爽一区二区三区精品| 国产精品99久久久久久董美香| xxx国产精品视频| 日产精品99久久久久久| 久久久精品国产亚洲成人满18免费网站| 97久久精品人妻人人搡人人玩| 亚洲精品无码成人片久久| 精品亚洲欧美无人区乱码| 99免费精品国产| 欧美精品亚洲精品日韩1818| 国产精品人人爽人人做我的可爱| 亚洲中文字幕久久精品无码APP| 久久久精品人妻无码专区不卡| 亚洲综合一区二区精品导航| 久久精品国产99国产精品澳门| 99久久精品午夜一区二区| 国产亚洲欧美精品久久久| 久久精品国产清高在天天线| 亚洲日韩精品无码一区二区三区| 日韩专区亚洲精品欧美专区| 精品亚洲欧美中文字幕在线看| 国产精品亚洲产品一区二区三区| 91精品国产福利在线观看麻豆| 国产精品一级香蕉一区| 2022精品天堂在线视频| 99精品国产在热久久| 国产精品水嫩水嫩| 国产亚洲精品岁国产微拍精品| 久久亚洲精品成人AV| 久久这里只有精品18| 久久久久久久久无码精品亚洲日韩| 亚洲国产精品一区二区久久hs| 色偷偷88888欧美精品久久久| 亚洲国产精品va在线播放| 欧美精品欧美人与动人物牲交| 久久国产免费观看精品3|